SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

Xultophy

NVO·NOVO NORDISK A S
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed (FDA approval November 21, 2016).
Why 3/10
Xultophy is an already-approved, marketed drug (FDA approved November 2016) with no pending PDUFA, pivotal readout, or regulatory decision scheduled in the next 12 months. It is a small part of Novo Nordisk's massive diabetes portfolio, which is dominated by semaglutide products. The impact score is 3 because the drug is commercialized with no binary catalyst ahead.
Actionable Insight NEUTRAL

Xultophy is an approved, marketed drug with no upcoming binary catalyst. The key event to watch is the projected loss of exclusivity around November 2028, which could open the door to biosimilar competition. For Novo Nordisk investors, Xultophy is a minor product within a portfolio dominated by semaglutide (Ozempic, Wegovy, Rybelsus); any material news would likely come from the broader GLP-1 competitive landscape or patent challenges rather than Xultophy-specific developments.

Price Chart

Loading chart...

Executive Summary

Xultophy (insulin degludec and liraglutide, also known as IDegLira) is a once-daily fixed-ratio combination injectable for adults with type 2 diabetes, developed and marketed by Novo Nordisk (NVO). The FDA approved it in November 2016. It combines Tresiba (insulin degludec) with Victoza (liraglutide) in a single pen. As an already-approved, commercially established product with no pending regulatory catalysts, Xultophy is a mature asset within Novo Nordisk's vast diabetes portfolio. The company's investor focus is overwhelmingly on its semaglutide franchise (Ozempic, Wegovy, Rybelsus) and the newly launched oral Wegovy pill. Xultophy faces direct competition from Sanofi's Soliqua and is projected to face biosimilar competition around late 2028 when exclusivity expires.

How It Works

Xultophy is a once-daily injection that combines two diabetes medicines in one pen: insulin degludec (a long-acting insulin that provides steady blood-sugar control over 24 hours) and liraglutide (a GLP-1 receptor agonist that mimics a natural hormone to help the pancreas release insulin when blood sugar is high, slow digestion, and reduce appetite). It is used alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes.

Trial Status

Xultophy was approved by the FDA on November 21, 2016, following a 16-0 advisory committee vote in favor. It has been commercially available in the U.S. since early 2017 and is also approved in numerous other markets. No new pivotal trials are ongoing for this combination product.

The Two-Sided Case

▲ Bull Case4
Xultophy is an FDA-approved, commercially established product with a decade of real-world use and safety data, providing a steady revenue stream for Novo Nordisk.
The fixed-ratio combination of basal insulin (degludec) and GLP-1 (liraglutide) offers a convenient once-daily injection for type 2 diabetes patients who need both therapies, addressing a clear clinical need.
Liraglutide has demonstrated cardiovascular and renal protective benefits in high-risk type 2 diabetes patients, which may support continued prescribing preference.
No biosimilar competition has yet been approved, and patent protection extends to at least late 2028, providing several more years of market exclusivity.
▼ Bear Case4
Xultophy faces direct competition from Sanofi's Soliqua (insulin glargine/lixisenatide), which was approved by the FDA on the same day in November 2016 and targets the same patient population.
Projected loss of exclusivity around November 2028 (12-year biologic exclusivity estimate) opens the door to biosimilar competition, which could erode market share and pricing power.
Novo Nordisk's overall 2026 outlook includes a forecasted sales decline of 5-13% at constant exchange rates, reflecting pricing pressure and competition from Eli Lilly in the broader GLP-1 market.
Xultophy is a relatively mature product (approved in 2016) in a rapidly evolving diabetes landscape where newer GLP-1 drugs like semaglutide and tirzepatide offer superior efficacy.

Upcoming Catalysts

  • No near-term binary catalysts: Xultophy is an approved, marketed drug with no pending FDA decision or pivotal readout.
  • Longer-term: Projected loss of exclusivity around November 2028, which could enable biosimilar entry.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVO NORDISK A S 6-K NVO ·Originating report

Sources · 10

Hover a chip for the title
1 biospace.com2 drugs.com3 novonordisk.com4 reuters.com5 cliffbio.com6 dibesity.com7 drugs.com8 purplebooksearch.fda.gov9 axis-intelligence.com10 annualreport.novonordisk.com